| A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ... Cancer cell 8 (5), 407-419, 2005 | 784 | 2005 |
| Generation of peptide–MHC class I complexes through UV-mediated ligand exchange B Rodenko, M Toebes, SR Hadrup, WJE Van Esch, AM Molenaar, ... Nature protocols 1 (3), 1120-1132, 2006 | 610 | 2006 |
| Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family A Borodovsky, H Ovaa, N Kolli, T Gan-Erdene, KD Wilkinson, HL Ploegh, ... Chemistry & biology 9 (10), 1149-1159, 2002 | 569 | 2002 |
| Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome M Groll, CR Berkers, HL Ploegh, H Ovaa Structure 14 (3), 451-456, 2006 | 512 | 2006 |
| OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis TET Mevissen, MK Hospenthal, PP Geurink, PR Elliott, M Akutsu, ... Cell 154 (1), 169-184, 2013 | 434 | 2013 |
| Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity D Shin, R Mukherjee, D Grewe, D Bojkova, K Baek, A Bhattacharya, ... Nature 587 (7835), 657-662, 2020 | 369 | 2020 |
| Design and use of conditional MHC class I ligands M Toebes, M Coccoris, A Bins, B Rodenko, R Gomez, NJ Nieuwkoop, ... Nature medicine 12 (2), 246-251, 2006 | 363 | 2006 |
| Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin B Pang, X Qiao, L Janssen, A Velds, T Groothuis, R Kerkhoven, ... Nature communications 4 (1), 1-13, 2013 | 313 | 2013 |
| Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2 E Meulmeester, MM Maurice, C Boutell, AFAS Teunisse, H Ovaa, ... Molecular cell 18 (5), 565-576, 2005 | 309 | 2005 |
| CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib R Piva, B Ruggeri, M Williams, G Costa, I Tamagno, D Ferrero, V Giai, ... Blood, The Journal of the American Society of Hematology 111 (5), 2765-2775, 2008 | 295 | 2008 |
| Disease-associated prion protein oligomers inhibit the 26S proteasome M Kristiansen, P Deriziotis, DE Dimcheff, GS Jackson, H Ovaa, ... Molecular cell 26 (2), 175-188, 2007 | 293 | 2007 |
| Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib CR Berkers, M Verdoes, E Lichtman, E Fiebiger, BM Kessler, ... Nature methods 2 (5), 357-362, 2005 | 288 | 2005 |
| Structural basis of substrate discrimination and integrin binding by autotaxin J Hausmann, S Kamtekar, E Christodoulou, JE Day, T Wu, Z Fulkerson, ... Nature structural & molecular biology 18 (2), 198-204, 2011 | 284 | 2011 |
| Differential dependence of CD4+ CD25+ regulatory and natural killer-like T cells on signals leading to NF-κB activation M Schmidt-Supprian, J Tian, EP Grant, M Pasparakis, R Maehr, H Ovaa, ... Proceedings of the National Academy of Sciences 101 (13), 4566-4571, 2004 | 270 | 2004 |
| Chemical synthesis of ubiquitin, ubiquitin‐based probes, and diubiquitin F El Oualid, R Merkx, R Ekkebus, DS Hameed, JJ Smit, A de Jong, ... Angewandte Chemie 122 (52), 10347-10351, 2010 | 261 | 2010 |
| Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity PC Evans, H Ovaa, M Hamon, PJ Kilshaw, S Hamm, S Bauer, HL Ploegh, ... Biochemical Journal 378 (3), 727-734, 2004 | 259 | 2004 |
| On terminal alkynes that can react with active-site cysteine nucleophiles in proteases R Ekkebus, SI van Kasteren, Y Kulathu, A Scholten, I Berlin, PP Geurink, ... Journal of the American Chemical Society 135 (8), 2867-2870, 2013 | 246 | 2013 |
| Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity J van Loosdregt, V Fleskens, J Fu, AB Brenkman, CPJ Bekker, ... Immunity 39 (2), 259-271, 2013 | 243 | 2013 |
| Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials B C Potts, M X Albitar, K C Anderson, S Baritaki, C Berkers, B Bonavida, ... Current cancer drug targets 11 (3), 254-284, 2011 | 221 | 2011 |
| Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation HMHG Albers, A Dong, LA van Meeteren, DA Egan, M Sunkara, ... Proceedings of the National Academy of Sciences 107 (16), 7257-7262, 2010 | 215 | 2010 |
Paul GeurinkAssistant professor, LUMCVerified email at lumc.nl
